BALAXI · Balaxi Pharmaceuticals Ltd · Major Drugs
BALAXI · Balaxi Pharmaceuticals Ltd · Major Drugs
As of 05 Nov close
52-week range
50.1% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 51 days old
Revenue (latest Q)
₹81 Cr
Revenue YoY
PAT YoY
+348.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
0.6
P/S (TTM)
0.5
Sector P/E
29.7
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| BALAXI (this stock) | 54.1 | 0.6 | +0.9% | +1.0% | 0.23 | 0.0% |
| Aurobindo Pharma | 24.7 | 2.9 | +10.6% | +9.8% | 0.21 | 0.0% |
| Neuland Laboratories | 66.1 | 13 | +18.0% | +21.4% | 13.9 | +0.2% |
| Pfizer | 27.6 | 5.1 | +28.6% | +17.5% | 0.02 | +1.9% |
Promoter
stable
FII
falling 3q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: On August 6, 2026, Balaxi Pharmaceuticals Limited submitted an investor presentation detailing the financial results for the quarter ended June 30, 2026. The presentation highlighted a 14% year-over-year increase in consolidated revenue to ₹80.68 crore, with a gross profit margin improvement of 241 basis points to 46.5%. Profit after tax rose significantly to ₹1.29 crore from ₹0.29 crore in the previous year. Management noted the successful commencement of commercial production at their first pharmaceutical formulation facility in Hyderabad, which has received approvals for 31 products. The company reported a total of 980 registered products across key markets and emphasized ongoing efforts in institutional business expansion and backward integration. The document also outlined strategic goals for market presence in Africa and Latin America, alongside a focus on operational efficiency and sustainable value creation.
Management emphasized strong revenue growth and improved profitability.
Sourced from an exchange-filed presentation, dated 06 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Balaxi Pharmaceuticals Limited submitted an investor presentation detailing the financial results for the quarter and year ended March 31, 2026. Management reported that FY26 was a transformational year, with consolidated revenue of ₹270.17 crore, a decrease from ₹292.56 crore in FY25, attributed to an extended working capital cycle in the institutional business. However, revenue from Latin America grew by 11% year-over-year to ₹111.29 crore. Gross profit margins improved to 44.2%, reflecting a better business mix and market diversification. The company secured 49 new product registrations, bringing the total to 964. Management highlighted the completion of their first pharmaceutical formulation facility in Hyderabad, which aims to enhance supply chain reliability and operational efficiencies. The presentation also noted plans to discontinue the ancillary Building Hardware business to focus on pharmaceuticals and improve working capital efficiency.
The document presented both challenges in revenue and positive developments in operational expansion.
Sourced from an exchange-filed presentation, dated 29 May 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedBalaxi Pharmaceuticals Limited's FY2025-26 annual report highlights strategic initiatives focused on expanding its pharmaceutical platform through the Jadcherla manufacturing facility and enhancing market presence in Latin America and Angola. The company emphasizes improving margin quality, reducing reliance on contract manufacturing, and optimizing working capital. The report notes ongoing efforts to achieve WHO-GMP certification for Jadcherla, which is critical for institutional credibility and future market filings. Financially, the company has not faced defaults, regulatory actions, or material uncertainties affecting its going-concern status. The auditor's report confirms compliance with accounting standards and proper financial controls.
- Strategic focus on Jadcherla manufacturing and WHO-GMP certification to enhance institutional credibility.
- Expansion plans in Latin America and Angola, leveraging growing pharmaceutical import demand.
- No defaults, regulatory actions, or material uncertainties affecting going-concern status.
- Auditor confirms compliance with accounting standards and proper financial controls.
Key takeaway: Balaxi Pharmaceuticals is strategically expanding its manufacturing and market presence with no material financial or regulatory risks identified, supported by auditor compliance confirmations.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (3 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
3 occurrencesRecent (last 12 months)
The company was non-compliant with Regulation 17(1)(a) of the SEBI (LODR) Regulations, 2015, due to a delay of 27 days in appointing a Woman Independent Director, resulting in a fine of ₹1,35,000/- levied by the NSE.
Earlier (1-3 years ago)
The company was non-compliant with Regulation 17(1)(a) of SEBI (LODR) Regulations, 2015, due to a 27-day delay in appointing a Woman Independent Director, resulting in a fine of ₹1,35,000 plus applicable GST levied by NSE.
Older (3+ years ago)
The company received a letter from NSE for delayed compliance of Regulation 29(2) of SEBI (LODR) Regulations, 2015, and paid a fine of ₹ 11,800/-.
Routine disclosures
Contingent Liability
1 occurrenceEarlier (1-3 years ago)
The company has pending cases, claims by third parties, and other contingencies. Contingent losses considered probable are recorded as accruals, while possible ones are disclosed as contingent liabilities.
Related-Party Transaction
5 occurrencesRecent (last 12 months)
The company has a related party transaction involving a contribution to Balaxi Foundation, which is a trust controlled by the company in relation to CSR expenditure.
Earlier (1-3 years ago)
The company has transactions with related parties including reimbursements to directors, capital contributions to subsidiaries like Balaxi Global DMCC and Balaxi Healthcare Ecuador, and sales to various step-down subsidiaries.
The company has a related-party transaction involving a contribution to Balaxi Foundation, a trust controlled by the company, in relation to CSR expenditure.
Older (3+ years ago)
Balaxi Pharmaceuticals Limited had a capital contribution of ₹7.41 lakh to Balaxi Global DMCC and a loan from directors, which were repaid as of 31-Mar-2023.
The company has transactions with related parties, including rent, reimbursement of expenses to directors, directors' remuneration, sitting fees, KMP salary, CSR, capital contribution to Balaxi Global DMCC, and loans from directors.
Management & Board Governance
1 occurrenceRecent (last 12 months)
Mr. Mohith Kumar Khandelwal resigned as Company Secretary and Compliance Officer with effect from close of business hours on 29th January, 2026, and was succeeded by Mr. Aman Purohit appointed with effect from 25th March, 2026.